Get startedLog in
    Picture of Daiken Biomedical Co logo

    7780 — Daiken Biomedical Co Cashflow Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    Consumer DefensivesHighly SpeculativeMid CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Daiken Biomedical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSAnnual Audited Accounts
    Standards:
    IFRS
    IFRS    		—
    Status:FinalFinalFinal
    Net Income/Starting Line110195140
    Depreciation
    Amortisation
    Non-Cash Items0.9870.493-21.5
    Other Non-Cash Items
    Changes in Working Capital-69-91.6-70.5
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities41.610551.8
    Capital Expenditures-0.053—-1.25
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-31.9-6285.3
    Sale/Maturity of Investment
    Purchase of Investments
    Change in Net Intangibles
    Other Investing Cash Flow
    Cash from Investing Activities-32-6284.1
    Financing Cash Flow Items—-140—
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities1360.117718
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash14643.4853